Treatment optimisation in drug development

Study 06-03-2020

The current drug development paradigm is too drug-centred and does not sufficiently take into account the patients that will receive the new therapy. This has led to the emergence of a research gap between the pre-approval development of medicines and their post-approval use in real-world conditions. In this study, semi-structured interviews were performed with experts in drug development process. It offer an overview concerning the concept of treatment optimisation and potential policy options.

External author

This study has been written by Dr Denis Lacombe of the European Organisation for Research and Treatment of Cancer (EORTC), Robbe Saesen of the Catholic University of Leuven (KU Leuven) and EORTC, Stéphane Lejeune of EORTC, and Prof. Dr Isabelle Huys of KU Leuven, at the request of the Panel for the Future of Science and Technology (STOA) and managed by the Scientific Foresight Unit (STOA) within the Directorate-General for Parliamentary Research Services (EPRS) of the Secretariat of the European Parliament.